Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
On Tuesday morning, the pharma giant announced that its oral GLP-1 drug orforglipron successfully met all the key primary and secondary endpoints set for the drug in a Phase 3 trial
Slowing aging requires more than scavenging ROS
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
Inhibition of T-cell proliferation by Helicobacter pylori -glutamyl transpeptidase
US$ 28.70
US$ 27.23
US$ 26.93
US$ 20.05
US$ 21.76
